U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C24H36N2O18S3
Molecular Weight 736.74
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLUCOSULFONE

SMILES

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(NC([C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)S(O)(=O)=O)C=C2)S(O)(=O)=O

InChI

InChIKey=SQQCWHCJRWYRLB-AGNGBHFPSA-N
InChI=1S/C24H36N2O18S3/c27-9-15(29)17(31)19(33)21(35)23(46(39,40)41)25-11-1-5-13(6-2-11)45(37,38)14-7-3-12(4-8-14)26-24(47(42,43)44)22(36)20(34)18(32)16(30)10-28/h1-8,15-36H,9-10H2,(H,39,40,41)(H,42,43,44)/t15-,16-,17-,18-,19+,20+,21-,22-,23?,24?/m1/s1

HIDE SMILES / InChI

Description

Glucosulfone (Glucosulfone Free Acid, or Promin) is a compound used to treat mycobacterial infections, such as tuberculosis and leprosy. It is converted to dapsone in the body, which also has been shown to have therapeutic effects against dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinii (pneumonia), subcorneal pustular dermatosis and cystic acne. Once converted to dapsone, it has haemotoxic effects (destroying red blood cells, or disrupting blood clotting, potentially causing organ or tissue damage).

Approval Year

1945
29
Doses

Doses

DosePopulationAdverse events​
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Disc. AE: Allergic dermatitis...
Other AEs: Anemia, Leucopenia...
AEs leading to
discontinuation/dose reduction:
Allergic dermatitis (3%)
Other AEs:
Anemia (46%)
Leucopenia (3%)
Allergic dermatitis (16%)
Allergic rhinitis (1.5%)
Headache (grade 1)
Nausea (grade 1, 35%)
Vomiting (7%)
Erythema nodosum leprosum (3%)
Iridocyclitis (10%)
Lymphadenitis (1.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
AEs

AEs

AESignificanceDosePopulation
Allergic rhinitis 1.5%
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Lymphadenitis 1.5%
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Iridocyclitis 10%
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Allergic dermatitis 16%
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Erythema nodosum leprosum 3%
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Leucopenia 3%
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Allergic dermatitis 3%
Disc. AE
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Anemia 46%
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Vomiting 7%
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Headache grade 1
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Nausea grade 1, 35%
5 g 1 times / day multiple, intravenous
Studied dose
Dose: 5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/5950351/
Sourcing

Sourcing

Vendor/AggregatorIDURL
ABI Chem
AC1LAFKP
BOC Sciences
554-18-7
Compound Cloud
10440240
Compound Cloud
487090
eMolecules
110040929
NovoSeek
10440240
THE BioTek
bt-447769
https://www.thebiotek.com/product/others/bt-447769
ZINC
ZINC000008214572
http://zinc15.docking.org/substances/ZINC000008214572
ZINC
ZINC000095628283
http://zinc15.docking.org/substances/ZINC000095628283
ZINC
ZINC000095628284
http://zinc15.docking.org/substances/ZINC000095628284
Patents

Patents

7790905
107
7927613
119
Name Type Language
SN-166 FREE ACID
Preferred Name English
GLUCOSULFONE
MART.   WHO-DD  
Common Name English
GLUCOSULFONE FREE ACID
Common Name English
GLUCOSULFONE [MART.]
Common Name English
GLUCOSULPHONE FREE ACID
Common Name English
4,4'-DIAMINOPHENYLSULFONE-N,N-DI(DEXTROSE SULFONATE)
Common Name English
Glucosulfone [WHO-DD]
Common Name English
D-GLUCITOL, 1,1'-(SULFONYLBIS(4,1-PHENYLENEIMINO))BIS(1-DEOXY-1-SULFO-
Common Name English
4,4'-DIAMINOPHENYLSULPHONE-N,N-DI(DEXTROSE SULPHONATE)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C849
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
NDF-RT N0000175483
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
Code System Code Type Description
CAS
551-89-3
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
ChEMBL
CHEMBL2105860
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
SMS_ID
100000084227
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
PUBCHEM
487090
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
MESH
C037441
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
WIKIPEDIA
Glucosulfone
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
NCI_THESAURUS
C87218
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
EPA CompTox
DTXSID70873667
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
DRUG CENTRAL
1308
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
FDA UNII
JX8G4WPC8D
Created by admin on Mon Mar 31 18:05:25 GMT 2025 , Edited by admin on Mon Mar 31 18:05:25 GMT 2025
PRIMARY
SALT/SOLVATE (PARENT)
Structure of GLUCOSULFONE SODIUM
SUBSTANCE RECORD
Structure of GLUCOSULFONE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966